" class="no-js "lang="en-US"> Xavier Treton - Medtech Alert
Monday, August 11, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Xavier Treton

Xavier Treton

About Xavier Treton

Co-founder

  • Professor of Gastroenterology at Beaujon Hospital, APHP, Paris,

  • Expert in IBD, clinical and translational research (Biomarkers)

  • 84 publications (Pubmed)

  • H-index 27 (Google Scholar)

  • 11 patents, Cofounder Inception IBD (Versant Ventures, Celgene)

  • Head of GI tissueBank, Beaujon Hospital

Related Story

Appointments

 Thabor Therapeutics Appoints Jérémie Mariau as Ceo | Pharmtech Focus

Thabor Therapeutics Appoints Jérémie Mariau as Ceo

May 18 2022

Thabor Therapeutics, a company developing an innovative treatment for patients living with chronic mucosal inflammatory […]